20^th European Gastroenterology and Therapeutics Congress

About Conference:

The 20th European Gastroenterology and Therapeutics Congress is scheduled to take place on November 17–18, 2025, in the iconic city of Paris, France. This leading scientific conference aims to bring together global experts, researchers, clinicians, and industry professionals to discuss the latest breakthroughs and foster collaborative dialogue in the field of gastroenterology. With the theme “Advancing Frontiers in Gastroenterology and Digestive Health,” the congress seeks to address pressing challenges and explore innovative solutions in managing gastrointestinal and liver diseases worldwide.

Gastroenterology 2025 offers a comprehensive scientific agenda covering a broad spectrum of topics including gastrointestinal oncology, endoscopic innovations, inflammatory bowel diseases, liver disorders, microbiome and gut health, pediatric gastroenterology, and nutritional and metabolic therapies. Esteemed keynote speakers will deliver high-impact lectures highlighting state-of-the-art research, while engaging sessions such as oral presentations, hands-on workshops, and poster exhibitions will allow participants to share findings, enhance clinical skills, and gain practical insights into evolving trends in digestive health care. The event also offers continuing medical education (CME) opportunities, making it invaluable for professionals seeking both knowledge and accreditation.

Paris, with its rich history, cultural charm, and world-renowned landmarks, provides an inspiring and memorable setting for this international congress. Delegates can enjoy the city’s renowned cuisine, explore its museums and historic sites, and engage in social events designed to foster meaningful professional connections. With a focus on scientific excellence, professional development, and cultural experience, the 20th European Gastroenterology and Therapeutics Congress promises to be a landmark event for anyone involved in digestive disease research, diagnosis, and treatment.
 

Sessions&Tracks

Track 1: Advances in Gastrointestinal Therapeutics
Advances in gastrointestinal therapeutics are transforming the management of digestive diseases through precision medicine, novel drug formulations, and biologics. Innovative treatments now target molecular pathways involved in conditions like inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS). Biologic agents such as anti-TNF and anti-integrin therapies have shown promising outcomes in IBD, reducing flare-ups and promoting mucosal healing. Personalized medicine, guided by genetic, microbial, and immune profiling, allows for tailored therapies that minimize side effects and maximize efficacy. Additionally, targeted drug delivery systems, such as pH-sensitive capsules and nanoformulations, enhance bioavailability and reduce systemic exposure. The integration of dietary and microbiome-based interventions also plays a crucial role in long-term disease control. This session will explore cutting-edge therapies, recent clinical trial results, and the future of individualized treatment plans in gastroenterology, offering clinicians new tools to enhance patient outcomes.

Track 2: Microbiome and Gut Health
The human gut microbiome has emerged as a key regulator of gastrointestinal health, metabolism, immunity, and even mental well-being. This session will delve into the complex relationship between the microbiome and digestive diseases, highlighting how dysbiosis—an imbalance in gut bacteria—contributes to conditions like IBD, IBS, colorectal cancer, and liver disease. Advancements in microbiome research have paved the way for targeted interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT), which are showing promise in restoring gut balance and alleviating symptoms. Cutting-edge metagenomic and metabolomic tools now allow researchers to identify microbial signatures associated with specific disorders, enabling early diagnosis and personalized therapy. The session will also cover the impact of diet, antibiotics, and lifestyle on gut flora, as well as future directions in microbiome engineering. Understanding and harnessing the microbiome represents a frontier in preventative and therapeutic gastroenterology, with broad implications for systemic health.

Track 3: Endoscopic Innovations and Techniques
Endoscopic technologies have rapidly advanced, allowing for more precise, minimally invasive diagnostics and therapeutic interventions in gastroenterology. This session focuses on next-generation tools and techniques that are reshaping endoscopic practice, including high-definition imaging, endoscopic ultrasound (EUS), confocal laser endomicroscopy, and AI-assisted diagnostics. New methods such as peroral endoscopic myotomy (POEM), endoscopic submucosal dissection (ESD), and endoscopic sleeve gastroplasty (ESG) are expanding the role of endoscopy beyond detection to effective treatment of conditions like achalasia, early GI cancers, and obesity. The integration of robotics and smart scopes is enhancing procedural accuracy and reducing complications. These innovations improve patient outcomes by reducing hospital stays, minimizing invasiveness, and allowing early-stage interventions. This session will provide practical insights into the application of these technologies, training considerations, and evidence-based outcomes, equipping gastroenterologists with the latest tools to deliver cutting-edge care.

Track 4: Inflammatory Bowel Disease (IBD): Insights and Advancements
Inflammatory Bowel Disease (IBD), comprising Crohn’s disease and ulcerative colitis, remains a complex and chronic inflammatory condition of the gastrointestinal tract. This session explores the latest scientific and clinical advancements in IBD pathogenesis, diagnosis, and treatment. New insights into immune dysregulation, genetic predisposition, and microbiome interactions are driving innovative therapeutic approaches. The emergence of biologics, JAK inhibitors, and gut-selective agents has revolutionized disease management by targeting specific immune pathways, leading to better mucosal healing and fewer relapses. Additionally, non-invasive biomarkers like fecal calprotectin and imaging modalities are enhancing early diagnosis and disease monitoring. Personalized treatment algorithms and therapeutic drug monitoring are improving long-term outcomes and reducing adverse effects. The session will also address pediatric IBD, lifestyle modification strategies, and emerging trends like stem cell therapy. With a multidisciplinary approach, these advancements offer renewed hope for improving quality of life in patients suffering from IBD.

Track 5: Liver Diseases and Hepatology
This session focuses on the evolving landscape of liver diseases and hepatology, covering common and complex conditions such as hepatitis, fatty liver disease (NAFLD/NASH), cirrhosis, and liver cancer. Liver health is increasingly affected by metabolic syndrome, alcohol use, viral infections, and autoimmune conditions, making timely diagnosis and targeted treatment more critical than ever. Innovations in liver imaging (like elastography and FibroScan), non-invasive biomarkers, and genetic testing are improving early detection of liver fibrosis and cirrhosis. Therapeutic advances, including antiviral therapies for hepatitis B and C, novel agents for NASH, and immunotherapies for hepatocellular carcinoma, are enhancing patient survival and quality of life. The session will also highlight the role of liver transplantation, donor optimization, and regenerative medicine, including bioengineered liver tissue and stem cell therapy. A multidisciplinary and preventive approach, coupled with personalized medicine, is now central to managing liver diseases in both acute and chronic stages.

Track 6: Colorectal Cancer: Prevention, Screening, and Treatment
Colorectal cancer (CRC) is one of the most prevalent and preventable malignancies worldwide. This session addresses current trends in the prevention, early detection, and treatment of CRC, emphasizing the importance of timely screening and risk stratification. Colonoscopy remains the gold standard for CRC screening, but advancements in non-invasive methods such as stool DNA tests, FIT, and liquid biopsies are expanding accessibility and compliance. Genetic testing and molecular profiling are refining risk assessment, enabling earlier interventions and personalized treatment strategies. Minimally invasive surgical techniques, immunotherapy, and targeted agents like EGFR and VEGF inhibitors have transformed the therapeutic landscape, improving survival rates even in advanced disease. The session also covers hereditary syndromes like Lynch syndrome and FAP, with recommendations for surveillance and prophylactic measures. By integrating public health strategies, patient education, and cutting-edge research, CRC prevention and treatment continue to evolve, aiming for earlier detection and better long-term outcomes.

Track 7: Gastrointestinal Infections and Antimicrobial Resistance
Gastrointestinal (GI) infections, caused by bacteria, viruses, parasites, or fungi, remain a major global health concern, especially in developing regions. This session explores the diagnosis, treatment, and prevention of common and emerging GI infections such as Clostridioides difficile, Helicobacter pylori, norovirus, rotavirus, and parasitic infestations. The growing challenge of antimicrobial resistance (AMR) in treating these infections is a key focus, as misuse and overuse of antibiotics continue to reduce treatment effectiveness. Experts will discuss novel diagnostic tools like multiplex PCR panels and rapid antigen detection that support faster identification of pathogens. Additionally, advances in vaccines, phage therapy, microbiome restoration (e.g., fecal microbiota transplantation), and host-targeted therapies offer alternative strategies to tackle resistant pathogens. Public health measures, infection control, and antimicrobial stewardship programs are crucial to reducing transmission and resistance rates. This session provides a platform for understanding the global burden of GI infections and innovations in combating AMR in gastroenterology.

Track 8: Functional GI Disorders: IBS and Beyond
Functional gastrointestinal disorders (FGIDs), especially Irritable Bowel Syndrome (IBS), significantly affect patient quality of life and are a major burden on healthcare systems. Characterized by chronic abdominal discomfort, bloating, and altered bowel habits without structural abnormalities, FGIDs are now understood to involve gut-brain axis dysregulation, altered motility, visceral hypersensitivity, and microbiome imbalance. This session delves into advances in diagnosing and managing IBS and related conditions like functional dyspepsia and functional constipation. While diagnosis remains clinical, enhanced criteria (e.g., Rome IV) and biomarkers like gut peptides and microbial signatures are being explored. Treatment strategies are evolving with the use of probiotics, low FODMAP diets, behavioral therapies like cognitive behavioral therapy (CBT), and novel agents such as gut-specific serotonin modulators and bile acid sequestrants. The session also highlights the importance of patient-centered care, psychological assessment, and lifestyle interventions in improving long-term outcomes. Integrating personalized approaches is key to managing these often misunderstood conditions.

Track 9: Pediatric Gastroenterology: Challenges and Innovations
Pediatric gastroenterology addresses unique gastrointestinal and liver disorders affecting infants, children, and adolescents. This session highlights the clinical challenges and latest innovations in diagnosing and treating pediatric GI conditions such as gastroesophageal reflux disease (GERD), celiac disease, inflammatory bowel disease (IBD), biliary atresia, and pediatric liver failure. The physiological and nutritional needs of children differ significantly from adults, necessitating age-appropriate diagnostic tools, dosing, and care protocols. Advances in pediatric endoscopy, non-invasive diagnostic biomarkers, and imaging modalities are enabling earlier and more accurate diagnosis. Nutritional management, including elemental diets and growth monitoring, plays a critical role in managing chronic conditions like IBD and celiac disease. Furthermore, genetic and metabolic testing are uncovering rare congenital GI disorders, allowing for early interventions. The session also explores the impact of early-life microbiome development on long-term gut health. By focusing on multidisciplinary, family-centered care, the field continues to evolve toward better outcomes for young patients.

Track 10: GI Oncology: Colorectal and Pancreatic Cancers
Gastrointestinal oncology remains a key area of focus due to the high global burden of colorectal and pancreatic cancers. This session delves into the latest advances in early detection, diagnostics, treatment, and personalized medicine for GI malignancies. Colorectal cancer, often preventable through routine screening, benefits from innovations in non-invasive diagnostics like fecal DNA testing, liquid biopsy, and AI-enhanced colonoscopy. Pancreatic cancer, known for its late diagnosis and poor prognosis, is being tackled through biomarker discovery, targeted therapies, and immunotherapies. Experts will explore precision oncology approaches, molecular profiling, and the role of the tumor microenvironment in therapy resistance. This track also highlights the integration of minimally invasive surgery, neoadjuvant therapies, and patient-specific treatment planning. Emphasis will be placed on improving survival rates, enhancing quality of life, and addressing disparities in access to care. The session serves as a comprehensive update for clinicians, researchers, and policymakers tackling the evolving challenges in GI oncology.

Track 11: Celiac Disease and Gluten-Related Disorders
Celiac disease and gluten-related disorders are increasingly recognized worldwide, affecting individuals across all age groups. This session explores the pathophysiology, diagnosis, management, and evolving research on celiac disease, non-celiac gluten sensitivity, and wheat allergy. Celiac disease is an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals, leading to intestinal damage and malabsorption. Diagnosis relies on serologic testing, HLA typing, and confirmatory intestinal biopsy, though newer diagnostic approaches like capsule endoscopy and point-of-care tests are emerging. Management primarily involves a lifelong gluten-free diet, but adherence challenges and hidden gluten sources complicate treatment. Researchers are developing non-dietary therapies, including enzyme therapy, tight junction modulators, and immunotherapies to improve patient quality of life. This session also examines the psychosocial impact of gluten-free living and the role of dietitians in patient education. The latest updates in diagnostic criteria, biomarkers, and gluten-free product regulation will be discussed to support better outcomes.

Track 12: Liver Cirrhosis and Complications
Liver cirrhosis, the advanced stage of chronic liver disease, is a major contributor to global morbidity and mortality. This session focuses on the pathogenesis, complications, and management of cirrhosis arising from various causes such as alcohol-related liver disease, chronic hepatitis B and C, and non-alcoholic steatohepatitis (NASH). Key complications—including portal hypertension, hepatic encephalopathy, variceal bleeding, ascites, and hepatocellular carcinoma—will be discussed with an emphasis on early recognition and intervention. The session highlights advancements in non-invasive diagnostic tools like transient elastography (FibroScan), serum fibrosis markers, and imaging techniques to assess liver fibrosis and function. Therapeutic strategies such as transjugular intrahepatic portosystemic shunt (TIPS), endoscopic band ligation, and targeted pharmacologic therapies will be explored. Multidisciplinary care models, nutritional support, and transplant evaluation protocols are vital in managing decompensated cirrhosis. By focusing on both prevention and comprehensive management, this session aims to improve patient outcomes and quality of life.
 

Track 13: Non-Alcoholic Fatty Liver Disease (NAFLD) and NASHNon-Alcoholic Fatty Liver Disease (NAFLD) and its progressive form, Non-Alcoholic Steatohepatitis (NASH), are becoming the most common chronic liver conditions globally due to rising rates of obesity and metabolic syndrome. This session highlights the pathophysiology, diagnosis, and management of NAFLD/NASH, focusing on its metabolic links and long-term liver-related complications, including cirrhosis and hepatocellular carcinoma. As there are currently no approved pharmacologic treatments, lifestyle modification remains the cornerstone of therapy. However, promising drug candidates targeting insulin resistance, fibrosis pathways, and inflammation are under investigation. This track also explores the use of non-invasive biomarkers, imaging modalities like MRI-PDFF and FibroScan, and risk stratification tools to avoid unnecessary biopsies. Experts will discuss the implications of NAFLD in children and its overlap with cardiovascular risk. With multidisciplinary care being essential, this session aims to advance understanding and awareness of NAFLD/NASH among clinicians, hepatologists, and public health professionals to better address this silent epidemic.

Track 14: Inflammatory Bowel Disease (IBD): Crohn’s and Ulcerative Colitis
Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition that significantly impacts patients’ quality of life. This session focuses on the latest advancements in pathogenesis, diagnostics, and management strategies for IBD. With growing insights into the role of the microbiome, immune dysregulation, and genetic susceptibility, targeted biologic and small molecule therapies are transforming treatment paradigms. The session explores novel therapeutic agents, including JAK inhibitors, S1P modulators, and anti-integrins, as well as personalized treatment approaches based on therapeutic drug monitoring. Innovations in imaging and endoscopic technologies are also improving disease monitoring and mucosal healing assessments. Special emphasis will be given to pediatric IBD, post-surgical recurrence, nutrition therapy, and extraintestinal manifestations. Attendees will gain insights into multidisciplinary IBD care, patient education, and emerging research on disease modification and remission strategies. The goal is to optimize clinical outcomes and long-term disease management through precision medicine.

Track 15: Peptic Ulcer Disease and H. pylori Infection
Peptic Ulcer Disease (PUD), primarily caused by Helicobacter pylori infection or NSAID use, continues to be a major gastrointestinal issue worldwide. This session provides comprehensive insights into the pathogenesis, clinical presentation, and management of PUD, with a particular focus on the evolving landscape of H. pylori treatment. Although incidence has declined in some regions due to better hygiene and eradication therapy, resistance to standard antibiotics poses a growing challenge. The session explores current diagnostic tools such as urea breath tests, stool antigen testing, and endoscopy, alongside updates on effective eradication regimens including quadruple therapies, tailored treatments, and the role of probiotics. Attendees will also learn about complications such as GI bleeding, perforation, and gastric outlet obstruction. This track emphasizes preventive strategies, including appropriate NSAID use and the role of PPIs, and updates on surveillance for gastric malignancies in high-risk populations. It is essential for clinicians aiming for evidence-based ulcer management.

Track 16: Celiac Disease and Gluten-Related Disorders
Celiac disease is an autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals, leading to inflammation and villous atrophy in the small intestine. This session delves into the pathogenesis, clinical spectrum, and diagnostic challenges of celiac disease and other gluten-related disorders, including non-celiac gluten sensitivity and wheat allergy. While classic gastrointestinal symptoms are well known, the session also covers atypical presentations such as anemia, infertility, neurological symptoms, and dermatitis herpetiformis. Diagnostic approaches, including serologic markers (tTG, EMA), HLA typing, and duodenal biopsy, will be discussed alongside updates in non-invasive diagnostics. The mainstay of treatment—a lifelong gluten-free diet—poses significant challenges, making patient education, monitoring, and support critical. Experts will explore emerging therapies under investigation that target immune modulation and enzymatic degradation of gluten. This session also highlights the importance of differentiating between celiac disease and other causes of enteropathy, ensuring accurate diagnosis and personalized care for patients.

Track 17: Gastrointestinal Oncology: From Screening to Targeted Therapies
Gastrointestinal (GI) cancers—including colorectal, gastric, esophageal, liver, and pancreatic cancers—are among the leading causes of cancer-related mortality worldwide. This session provides a comprehensive overview of current trends in GI oncology, from early detection to advanced therapeutic strategies. Emphasis will be placed on the importance of screening programs, such as fecal immunochemical tests (FIT) and colonoscopy, in detecting precancerous lesions and early-stage colorectal cancer. Advances in molecular biology and genomics have led to the development of targeted therapies and immunotherapies, transforming treatment landscapes for many GI malignancies. Participants will explore biomarker-driven approaches, personalized medicine, and the integration of next-generation sequencing in clinical practice. The session also addresses challenges in managing advanced-stage cancers, the role of neoadjuvant and adjuvant therapy, and palliative care strategies. Case discussions and expert panels will provide attendees with practical insights into multidisciplinary cancer care, improving outcomes for patients with GI malignancies.

Track 18: Gastrointestinal Bleeding: Acute and Chronic Management
Gastrointestinal (GI) bleeding is a common and potentially life-threatening condition that requires prompt diagnosis and management. This session focuses on both acute and chronic GI bleeding, covering upper and lower GI sources including peptic ulcers, varices, diverticulosis, angiodysplasia, and malignancies. Attendees will learn about initial resuscitation, risk stratification, and the role of endoscopy in both diagnosis and therapeutic intervention. Advances in endoscopic techniques—such as band ligation, hemostatic sprays, over-the-scope clips (OTSC), and Doppler-guided procedures—are enhancing the management of GI bleeding with better outcomes. The session also addresses the role of imaging modalities like CT angiography, radionuclide scans, and capsule endoscopy in cases of obscure bleeding. Special attention is given to managing bleeding in anticoagulated patients and those with portal hypertension. Chronic GI bleeding, often presenting as iron-deficiency anemia, will be discussed with a focus on long-term management and investigation. This session equips clinicians with evidence-based strategies to reduce morbidity and mortality.

Track 19: Functional Gastrointestinal Disorders and Gut-Brain Axis
Functional gastrointestinal disorders (FGIDs), such as irritable bowel syndrome (IBS), functional dyspepsia, and chronic constipation, are characterized by persistent GI symptoms without detectable structural or biochemical abnormalities. This session explores the evolving understanding of FGIDs through the lens of the gut-brain axis, a complex bidirectional communication system linking the central nervous system with the enteric nervous system. Topics include how stress, emotions, and psychological factors influence gut motility, sensitivity, and microbiota composition. Attendees will gain insights into Rome IV criteria, the latest diagnostic framework for FGIDs, and how they guide classification and management. Treatment strategies now encompass dietary interventions (e.g., low-FODMAP diet), pharmacotherapy, gut-directed hypnotherapy, and neuromodulators. Advances in understanding visceral hypersensitivity, altered motility, and microbiome alterations are paving the way for personalized medicine in FGIDs. This session emphasizes the importance of a multidisciplinary approach involving gastroenterologists, psychologists, dietitians, and primary care to improve patient quality of life.

Track 20: Emerging Trends and Future Directions in Gastroenterology
This session highlights the most promising innovations and future directions shaping the landscape of gastroenterology and hepatology. It covers breakthroughs in molecular diagnostics, precision medicine, and AI-assisted imaging, as well as novel therapeutic strategies such as microbiome modulation, regenerative medicine, and RNA-based therapies. The session also explores how digital health tools—including remote monitoring, tele-endoscopy, and wearable GI sensors—are transforming patient engagement and care delivery. Attention is given to how global health challenges such as antimicrobial resistance, rising GI cancer incidence, and increasing prevalence of lifestyle-related liver and bowel diseases are being addressed through policy, education, and research. A focus on equity in GI care delivery, especially in underserved regions, is also emphasized. By examining future research priorities and collaborative models, this track offers a forward-thinking view on how clinicians, researchers, and industry leaders can shape a more effective, personalized, and equitable future in digestive health.

 

Market Analysis

The global gastroenterology and gastrointestinal therapeutics market has seen steady growth and is projected to expand significantly from 2020 through 2035. This surge is driven by increasing prevalence of gastrointestinal disorders, advancements in minimally invasive technologies, rising healthcare expenditure, and greater awareness of digestive health. The global GI market was valued at approximately $48 billion in 2020 and is expected to surpass $75 billion by 2035, with a compound annual growth rate (CAGR) of 4.5–6.2%.Diseases such as colorectal cancer (CRC), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), non-alcoholic fatty liver disease (NAFLD), and irritable bowel syndrome (IBS) are on the rise due to factors like sedentary lifestyles, poor diet, increased alcohol consumption, and stress. These trends are fueling demand for both diagnostics and therapeutics in the gastroenterology field.

Advancements in endoscopic tools, imaging systems, and robotic-assisted surgery have significantly improved diagnostic accuracy and treatment outcomes. Technologies such as capsule endoscopy, AI-assisted colonoscopy, and digital pathology are transforming the GI landscape. The adoption of biologics and biosimilars for IBD and novel liver therapies has opened new avenues for treatment.North America holds the largest share due to strong R&D, advanced technology adoption, and high prevalence of CRC and IBD.Europe ranks second, with countries like Germany, France, and the UK leading the way in screening programs, endoscopy innovation, and liver disease management.Asia-Pacific is the fastest-growing market due to a large patient population, increasing cancer rates, and expanding healthcare access in countries like India and China.Latin America and Middle East & Africa are emerging markets, supported by growing public health initiatives, screening programs, and pharmaceutical expansion.By 2035, the gastroenterology market is expected to see deeper integration of AI, personalized medicine, microbiome-targeted therapies, and regenerative techniques, alongside greater emphasis on preventive care, digital health, and population-wide screening efforts.

In conclusion, the global gastroenterology market is positioned for robust expansion, with continuous innovation, rising disease burden, and enhanced global healthcare access driving long-term growth.

Past Conference Report: EuroGastro 2024

EuroGastro 2024, the 19th European Gastroenterology and Therapeutics Congress, was a landmark event held in Rome, Italy, bringing together leading experts, clinicians, researchers, and industry professionals in the field of gastroenterology. Organized under the theme “Innovations in Digestive Health and GI Therapeutics”, the conference served as an interdisciplinary platform to exchange ideas, discuss clinical advancements, and showcase cutting-edge research.The event featured keynote lectures, scientific sessions, symposia, poster and video presentations, and interactive panel discussions. Topics ranged from advancements in endoscopy, hepatology, colorectal surgery, GI oncology, to innovations in gut microbiome research and therapeutic interventions for IBD, IBS, GERD, and NAFLD.

Attendees included gastroenterologists, hepatologists, endoscopy technicians, oncologists, researchers, academic professionals, and industry leaders from across Europe, Asia, North America, and the Middle East. The conference fostered vibrant networking, collaborative discussions, and strategic insights into the future of GI care.Notable speakers shared clinical trial updates, novel AI-integrated diagnostics, and real-world data on the efficacy of biologics and biosimilars in GI diseases. The abstract submissions were highly competitive, and selected works were published in recognized scientific journals such as the Journal of Gastrointestinal & Digestive System and Clinical Gastroenterology Journal.

Overall, EuroGastro 2024 was a resounding success—setting a high standard for EuroGastro 2025 in Paris, France. The event highlighted the increasing global collaboration in tackling digestive diseases and showcased the growing momentum in innovation and therapeutic advancements.